Live feed08:00:00·8dPRReleasevia QuantisnowCalidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026ByQuantisnow·Wall Street's wire, on your screen.CLDI· Calidi Biotherapeutics Inc.Health Care
